Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AFT Pharmaceuticals Limited (AFT.NZ)
NZD3.91
-0.01 (-0.26%)
NZ NZE Healthcare Drug Manufacturers - Specialty & Generic
Address
129 Hurstmere Road 622
Auckland, NZ
Auckland, NZ
CEO
Hartley Atkinson
Website
aftpharm.com
IPO
2015-12-21
ISIN NZAFTE0001S4
Also trades on
Australian Securities Exchange · AFP.AX (AUD)
New Zealand Exchange · AFT.NZ (NZD)
Description
AFT Pharmaceuticals, along with its subsidiaries, focuses on the creation and distribution of pharmaceutical products across New Zealand, Australia, Asia, and other global markets. Their extensive product range addresses a variety of health categories, including but not limited to allergy relief, cold and flu remedies, digestive health, eye care, first aid essentials, nail and oral care, pain management, skincare solutions, and nutritional supplements. This company was established in 1997 and its main office is located in Auckland, New Zealand.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
NZD3.91
-0.01 (-0.26%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
20.6K
Beta
0.42
Float Shares
30.48M
Free Float %
29.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.03% | +12.00% | +10.42% | +8.59% | +6.23% | +15.98% | +41.01% | +4.53% | -16.06% | +29.80% | +26.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.91
DCF (Unlevered)
3.70
-5.3%
DCF (Levered)
4.16
+6.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.71
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+24.0% ★ Q1'26: +25.0% (vs Q1'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+27.3% ★ Q1'26: -8.3% (vs Q1'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-6.3% Q1'26: -8.0% (vs Q1'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+9.8% Q1'26: +13.9% (vs Q1'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.5% ★ Q1'26: +33.2% (vs Q1'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: -11.8% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.89× Q1'26: 0.63× (vs Q1'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 2 Rev. Ana. 2 EPS Ana. |
Mar 2027 2 Rev. Ana. 2 EPS Ana. |
Mar 2028 2 Rev. Ana. 2 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
57.67M
est: 64.01M (-9.9%)
|
69.05M
est: 69.20M (-0.2%)
|
79.88M
est: 80.09M (-0.3%)
|
84.87M
est: 91.23M (-7.0%)
|
105.24M
est: 105.60M (-0.3%)
|
112.86M
est: 110.27M (+2.4%)
|
129.83M
est: 133.60M (-2.8%)
|
155.82M
est: 158.67M (-1.8%)
|
195.41M
est: 192.57M (+1.5%)
|
205.49M
est: 213.40M (-3.7%)
|
261.70M
259.09M – 264.31M
+22.6% YoY
|
303.90M
303.10M – 304.70M
+16.1% YoY
|
345.30M
342.80M – 347.80M
+13.6% YoY
|
389.70M
388.30M – 391.10M
+12.9% YoY
|
| EBITDA |
-9.32M
est: 8.32M (-211.9%)
|
-14.42M
est: 9.00M (-260.2%)
|
-9.67M
est: 10.42M (-192.9%)
|
3.96M
est: 11.86M (-66.6%)
|
21.04M
est: 13.73M (+53.2%)
|
12.43M
est: 14.34M (-13.3%)
|
21.12M
est: 17.38M (+21.5%)
|
20.40M
est: 20.64M (-1.2%)
|
27.72M
est: 25.05M (+10.7%)
|
21.52M
est: 27.84M (-22.7%)
|
34.14M
33.80M – 34.48M
+22.6% YoY
|
39.64M
39.54M – 39.75M
+16.1% YoY
|
45.04M
44.72M – 45.37M
+13.6% YoY
|
50.84M
50.65M – 51.02M
+12.9% YoY
|
| EBIT |
-9.58M
est: 7.66M (-225.2%)
|
-14.45M
est: 8.28M (-274.6%)
|
-10.01M
est: 9.58M (-204.5%)
|
6.16M
est: 10.91M (-43.6%)
|
19.94M
est: 12.63M (+57.8%)
|
11.33M
est: 13.19M (-14.1%)
|
21.12M
est: 15.98M (+32.1%)
|
18.67M
est: 18.98M (-1.6%)
|
25.71M
est: 23.04M (+11.6%)
|
18.86M
est: 25.41M (-25.8%)
|
31.16M
30.85M – 31.47M
+22.6% YoY
|
36.18M
36.09M – 36.28M
+16.1% YoY
|
41.11M
40.82M – 41.41M
+13.6% YoY
|
46.40M
46.23M – 46.57M
+12.9% YoY
|
| Net Income |
-11.95M
est: -30.94M (+61.4%)
|
-18.39M
est: -19.99M (+8.0%)
|
-12.72M
est: -13.84M (+8.1%)
|
-2.43M
est: -2.10M (-15.7%)
|
12.69M
est: 3.09M (+310.3%)
|
7.78M
est: 6.22M (+25.1%)
|
19.85M
est: 14.05M (+41.2%)
|
10.65M
est: 13.79M (-22.8%)
|
15.61M
est: 14.99M (+4.1%)
|
11.96M
est: 10.38M (+15.2%)
|
14.73M
14.48M – 15.72M
+41.9% YoY
|
19.71M
19.25M – 20.18M
+33.8% YoY
|
24.84M
23.18M – 26.42M
+26.0% YoY
|
30.78M
30.57M – 30.98M
+23.9% YoY
|
| SGA |
23.82M
est: 19.12M (+24.6%)
|
31.82M
est: 20.67M (+53.9%)
|
36.84M
est: 23.92M (+54.0%)
|
33.74M
est: 27.24M (+23.9%)
|
35.31M
est: 31.54M (+12.0%)
|
35.22M
est: 32.93M (+7.0%)
|
36.10M
est: 39.90M (-9.5%)
|
47.67M
est: 47.38M (+0.6%)
|
56.47M
est: 57.51M (-1.8%)
|
63.32M
est: 62.91M (+0.7%)
|
77.15M
76.38M – 77.92M
+22.6% YoY
|
89.59M
89.36M – 89.83M
+16.1% YoY
|
101.80M
101.06M – 102.54M
+13.6% YoY
|
114.89M
114.48M – 115.30M
+12.9% YoY
|
| EPS |
-0.43
est: -0.30 (-45.8%)
|
-0.19
est: -0.19 (+0.3%)
|
-0.13
est: -0.13 (+1.5%)
|
-0.02
est: -0.02 (-24.5%)
|
0.12
est: 0.03 (+306.8%)
|
0.07
est: 0.06 (+23.9%)
|
0.19
est: 0.13 (+41.8%)
|
0.10
est: 0.13 (-24.2%)
|
0.15
est: 0.15 (+2.0%)
|
0.11
est: 0.10 (+11.1%)
|
0.14
0.14 – 0.15
+45.5% YoY
|
0.19
0.18 – 0.19
+30.6% YoY
|
0.24
0.22 – 0.25
+25.8% YoY
|
0.29
0.29 – 0.30
+24.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
3.45M
OE per share TTM
0.04
Owner's Yield
0.85%
Maintenance CapEx ratio
4.81%
Maint CapEx / Avg PPE
2.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 3.0K | 0.39% |
| 2 | Dimensional - International Vector Equity ETF DXIV | 0.00% | 63.15 | 0.53% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
226.0K
Shares Outstanding
104.87M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hartley Atkinson | Co-Founder, Chief Executive Officer, MD & Executive Director | 1M | — |
| Marree Atkinson | Co-Founder, Chief of Staff & Executive Director | 272.1K | female |
| Ioana Stanescu | Chief Scientific Officer | — | female |
| Malcolm Tubby ICAEW ICANZ | Chief Financial Officer & Company Secretary | — | male |
| Murray Keith | Group Marketing Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AFT.NZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
